Beautiful sunset in Menorca Island, Spain with the sunraysrays of the sun coming through the clouds and falling towards the sea
During Seth Wilsons last ketamine treatment, he set an intention to see his late mother. Wilson, a 41-year-old sommelier who owns a wine shop in Chicago, has been dealing with depression and anxiety since he was 13 years old and sought psychedelic-assisted therapy to get better. Coincidentally, this session happened to be on what wouldve been his mothers 77th birthday. He put on eyeshades, headphones and sat back in a leather recliner as he was injected with 110 milligrams of the dissociative anesthetic ketamine.
Within seconds, he was blasted into the cosmos and felt her presence. His mother took him to experience her birth and showed him the afterlife.
I can remember being part of this liquid world and as we're in this space together, she said, your birth is my birth, and we are the same, Wilson recounts.
He says the experience helped him deal with the trauma of his mothers death and helped him manage his anxiety and depression by showing him there is more to life than the physical world.
This is the answer; this is what it feels like to be beyond Earth, his mother said to him. It was an incredibly profound and moving experience.
Humans have used psychedelics in cultural and religious rituals for thousands of years. Over the last 80 years, these powerful substances have been adopted for self-help, mental health, and recreational purposes. At the same time, Americans are becoming less religious. In 1999, 70% of Americans said they were a member of a church, synagogue or mosque but that number fell to 47% in 2020. The number of people affiliated with any religion has plummeted: 29% of Americans identified as agnostic or atheist in 2021, up from 18% in 2011, according to thePew Research Center.Now that the psychedelic renaissance is underway and companies and nonprofits are racing to get these molecules approved by the U.S. Food and Drug Administration as medicines when combined with therapy to treat depression and post-traumatic stress disorder, one question seems important: Is it the drugs, or is it divine experiences thats making people feel better?
In our apostate culture, could the secret be that we just all need some spirituality, and these molecules are helping?
For Wilson, he says the divine experience, coupled with multiple sessions of therapy over three weeks, gave him the breakthrough that decades of anti-depressants and traditional talk therapy couldnt.
Were all searching for the ineffable and its so deeply personal, he says. I think the word God can be triggering for people, but its about this trust and faith that there is something bigger and grander than ourselves. And that this physical world doesnt matter, and all our problems dont matterthere is something greater.
Alex Belser, the chief clinical officer of Cybin, a Toronto-based psychedelic therapeutics startup, has been studying psychedelics for two decades and has conducted clinical trials of psilocybin and MDMA as potential treatments for depression, substance use, post-traumatic stress disorder and obsessive-compulsive disorder.
Belser says eliciting mystical-type experiences is one of the prevailing theories about why psychedelic-assisted therapy reduces symptoms in patients with depression, anxiety, and other conditions. During many clinical trials, patients are given the Mystical Experience Questionnaire,a 30-question self-report that is used to measure the effects of hallucinogens. The questions a patient answers are rather woo-woodid you have a profound sense of unity, a strong sense of awe, a feeling of interconnectedness with other people and all things, a sense of ineffability, a sense of timelessness? but he says for many studies there has been a correlation between high mystical scores and greater reduction in a patients symptoms.
This is a strong predictor of effectiveness in psychedelic medicines, says Belser, who is a licensed psychologist and a psychedelic researcher at Yale University.
Belser says definitive conclusions cannot be drawn yet as the mechanism of action for psychedelic drugs is still a black box and too much weight should not be given to divine experiences.
Florian Brand, the CEO and cofounder of Atai Life Sciences, a publicly traded German biosciences company focused on psychedelics and mental health, says its still speculation but the mystical experience does seem to have some significance in patient outcomes.
There might be benefits [from the mystical experience], Brand says. I think there are multiple factors that could contribute to the efficacy, yet it's still early days to say that it's the divine experience.
I do think for many people the connection to spirituality and the divine often plays a very powerful, interesting role in the healing.
Atai is the largest investor in Compass Pathways, a U.K.-based clinical stage company that is developinga patented form of psilocybinthe active compound in magic mushroomsto be used in conjunction with therapy to treat depression. Having undergone a psychedelic-assisted therapy session with psilocybin, Brand says the mystical experience he had helped him.
From a spiritual perspective, I personally can say that I wasn't religious or spiritual at all before undergoing my very first psilocybin-assisted therapy session, says Brand. Coming out of it, I definitely have a different access to spirituality compared to going into the session.
Lars Christian Wilde, the president, chief business officer, and cofounder of Compass Pathways, says patients have different ways to describe a mystical experience but no matter the description an intense experience correlates to a positive therapeutic outcome.
Some people say, Wow, I met God, while others say, Wow, I understood that my ego is an illusion, says Wilde. Depending on what your cultural anchor you have a different way to describe that experience, but indeed, it seems to be critically important for the therapeutic effect of not only psilocybin, but probably many of the serotonergic substances.
In November, Compass Pathways published data from its much-anticipated phase 2b clinical trialon psilocybin-assisted therapy for treatment-resistant depression. The study found that patients who took a single psychedelic dose of psilocybin, 25mg, in conjunction with therapy reported almost immediate and significant reduction in depressive symptoms that lasted weeks compared with patients who were given a placebo dose.
Wilde says more research needs to be done but it seems that when a person has an intense psychedelic experience, they have a bigger reset effect on the brain.
The reason psychedelic drugs have been found to alleviate symptoms of depression and PTSD in clinical trials, it is thought, is due the signaling of the 5-HT-2A receptor, which sparks whats called neuroplasticity.Neuroplasticity helps the brain form new neural connections, which is believed to generate rapid and sustained positive mood effects. In a slate of studies, psilocybin-assisted psychotherapy and MDMA-assisted therapy have provided almost immediate reductions in symptoms of depression and PTSD after a single high dose. The effects last months in some patients.
Prescription sales for depression is estimated to be $50 billion a year globally, while the mental health market is worth about $100 billion in annual sales. Biotech analysts say that FDA-approved psychedelic-assisted therapy could seize billions in annual sales if approved by the FDA.
Natalie Ginsberg, the global impact officer of the Multidisciplinary Association for Psychedelic Studies, says there is a great history of the intersection between psychoactive drugs, religion, and healing. From medicine healers in indigenous cultures to the role of cannabis in Judaismthe drug is mentioned in the Torah and was found at an altar outside of Jerusalem from 800 B.C.
I do think for many people the connection to spirituality and the divine often plays a very powerful, interesting role in the healing, says Ginsberg.
Psychedelic research pioneer Rick Doblin, who founded the Multidisciplinary Association for Psychedelic Studies in 1986,has dedicated his lifes work to psychedelic drugs. MAPS is currently trying to bring MDMA-assisted therapy to market as an FDA-approved treatment for post-traumatic stress disorder. In May, his organization released data from its phase three trial on MDMA-assisted therapy with shockingly positive results. The double-blind, placebo-controlledstudyfound that 67% of participants who received MDMA combined with psychotherapy no longer qualified for a PTSD diagnosis, compared with 32% in the placebo group. Doblin is hopeful that FDA approval is within the next couple of years.
But Doblin says at least for patients with PTSD undergoing MDMA-assisted therapy, there is no connection between mystical experiences and better therapeutic outcomes. It doesn't seem to show up and be important to reduce PTSD symptoms, says Doblin.
Master of Molly: Rick Doblin, the founder of Multidisciplinary Association for Psychedelic Studies. MAPS is likely to become the first company to gain FDA approval for MDMA-assisted therapy to treat PTSD.
Doblin says the mystical experience does seem to have some benefits, especially for people with depression, but he is cautious to give these types of experiences too much credit.
There are people that get better without having a mystical experience and there are people that have a mystical experience without getting better, says Doblin. Correlation is not the same as causation.
Doblin says it is important to realize that the drugs are not the therapy, but that the drugs enhance therapy. The risk of pinning too much on achieving a mystical experience, Doblin explains, is that you can avoid dealing with and working through the problems that brought you to therapy in the first place. The point is to deal with your problems, not avoid them.
You [dont want to] just talk about, how, Oh, I'm all one with the universe, but then you come back down and yell at your wife, Doblin explains.
The best way to look at it is like the spectrum of the rainbow, Doblin continues. There's all these different colors, and these are all layers of consciousness, and you need all of them together. If you focus on just biography, like Freud did, and you ignore spirituality, it's incomplete. But if you focus only on the spiritual and not on the biographical, it's similarly incomplete.
More:
How Seeing God Might Be The Secret To The Most Cutting-Edge Mental Health Treatments - Forbes
- Review: Tripping on Utopia Complicates the History of Psychedelics - AOL - March 16th, 2024 [March 16th, 2024]
- Psychedelics Are Going Mainstream. Investing in Them Hasn't. - The Wall Street Journal - January 7th, 2024 [January 7th, 2024]
- Another Study Shows African Psychedelic Plant Ibogaine Treats Traumatic Brain Injury in Vets With 'Dramatic' Results - Good News Network - January 7th, 2024 [January 7th, 2024]
- Massachusetts Lawmakers Will Be Forced To Consider Psychedelics Legalization Measure That Activists Petitioned ... - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA to begin researching psychedelics as treatment option for veterans - Government Executive - January 5th, 2024 [January 5th, 2024]
- VA Is Funding New Research On Psychedelics' Benefits For Veterans With PTSD And Depression - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA ramps up study of psychedelic to treat PTSD - The American Legion - January 5th, 2024 [January 5th, 2024]
- Scientists predict DMT trip from cardiac activity - Big Think - January 5th, 2024 [January 5th, 2024]
- If psychedelics heal, how do they do it? | Proceedings of the National Academy of Sciences - pnas.org - January 5th, 2024 [January 5th, 2024]
- Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential | Molecular ... - Nature.com - January 5th, 2024 [January 5th, 2024]
- U.S. Rep. Correa supports using psychedelics to treat veterans with PTSD - New Santa Ana - January 5th, 2024 [January 5th, 2024]
- DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Psychedelics for Psych Conditions Made Their Mark in 2023 - Medpage Today - January 5th, 2024 [January 5th, 2024]
- 2023: A Good Trip Around the Sun for Psychedelics - The National Law Review - January 5th, 2024 [January 5th, 2024]
- Understanding the Role of the FDA in Advancing Psychedelic Therapy - Medriva - January 5th, 2024 [January 5th, 2024]
- MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics - Psychedelic Alpha - January 5th, 2024 [January 5th, 2024]
- Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care - Open Access Government - January 5th, 2024 [January 5th, 2024]
- The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes - Austin Chronicle - January 5th, 2024 [January 5th, 2024]
- This Forgotten Psychedelic Could Revolutionize Traumatic Brain Injury Treatment - Inverse - January 5th, 2024 [January 5th, 2024]
- A 'milestone' for psychedelics: Pentagon directed to study alternative treatments for veterans - Washington Times - January 5th, 2024 [January 5th, 2024]
- Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here's What's Next - Singularity Hub - January 5th, 2024 [January 5th, 2024]
- The top 8 psychedelic books you need to read | GreenState - GreenState - January 5th, 2024 [January 5th, 2024]
- Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC - Green Market Report - January 5th, 2024 [January 5th, 2024]
- DEA Calls For Even More THC, Psilocybin And DMT To Be Produced For Research In 2024 - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Here's What You Missed in Cannabis, Psychedelics This Week - TipRanks.com - TipRanks - January 5th, 2024 [January 5th, 2024]
- You're not tripping: State and local leaders give psychedelics another chance - Route Fifty - December 22nd, 2023 [December 22nd, 2023]
- Are Consciousness-Expanding Psychedelics Like Psilocybin More Effective Than Prozac, Zoloft, Xanax, and Other ... - Nautilus - December 22nd, 2023 [December 22nd, 2023]
- RFK, Ramaswamy And Williamson Push Psychedelics Reform On Presidential Campaign Trail - Marijuana Moment - December 22nd, 2023 [December 22nd, 2023]
- Peyote is the darling of the psychedelics renaissance. Indigenous users say it co-opts a sacred way of life - The Guardian US - December 22nd, 2023 [December 22nd, 2023]
- USask researchers explore untold history of psychedelics - News - University of Saskatchewan - USask News - December 22nd, 2023 [December 22nd, 2023]
- California Governor Says Psychedelics Have 'Profound' Healing Potential, But He's Undecided On Legalization Bill As ... - Marijuana Moment - September 25th, 2023 [September 25th, 2023]
- As psychedelic-assisted therapy grows, so does interest from a new group: chaplains - NPR - September 25th, 2023 [September 25th, 2023]
- This Maine City Moves Unanimously On Decriminalizing Psychedelics: Focus On Public Health - Benzinga - September 25th, 2023 [September 25th, 2023]
- Tech Leaders Are Finding Balance Through Microdosing Psychedelics - The Dales Report - September 25th, 2023 [September 25th, 2023]
- Chronic Pain Can Be Treated by Psychedelics, Survey Suggests - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Insights Into the First Psychedelic-Assisted Therapy Guidelines With ... - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Living with long-term cancer is depressing. Texas doctors say psychedelics could help - The Hill - July 19th, 2023 [July 19th, 2023]
- Couples Are Doing MDMA and Ketamine Therapy To Save Their Relationships - VICE - July 19th, 2023 [July 19th, 2023]
- The Way People Are Using Psychedelics Is Changing Amid Reform ... - Marijuana Moment - July 19th, 2023 [July 19th, 2023]
- [WATCH] Turn on, tune in, legalise: Could psychedelics be next in ... - MaltaToday - July 19th, 2023 [July 19th, 2023]
- Will Psychedelics Be Rescheduled After FDA Approval? - Harris Bricken - July 19th, 2023 [July 19th, 2023]
- The Psychedelic Preparedness Scale: A Tool to Optimize Trip ... - Filter - July 19th, 2023 [July 19th, 2023]
- How to Test Psychedelics for Adulterants with Testing Kits - Psychedelic Spotlight - July 19th, 2023 [July 19th, 2023]
- Cannabis Science Conference to debut in Providence, R.I., with ... - GlobeNewswire - July 19th, 2023 [July 19th, 2023]
- New Speaker Rivas weighs in on psychedelics, housing and health care worker minimum wage - Yahoo News - July 19th, 2023 [July 19th, 2023]
- TDR's Top 5 Psychedelic Developments For The Week Of July 10 - The Dales Report - July 19th, 2023 [July 19th, 2023]
- Psychedelic Treatment with Psilocybin Relieves Major Depression, Study ... - February 20th, 2023 [February 20th, 2023]
- Johns Hopkins Launches Center For Psychedelic Research - February 20th, 2023 [February 20th, 2023]
- Psilocybin Treatment for Major Depression Effective for Up to a Year ... - February 20th, 2023 [February 20th, 2023]
- Inside the Johns Hopkins Psilocybin Playlist - Hopkins Medicine - February 20th, 2023 [February 20th, 2023]
- Research Story Tip: Psychedelic Drug Psilocybin Tamps Down Brains Ego ... - February 20th, 2023 [February 20th, 2023]
- Psychedelics: Risks, benefits, and more - Medical News Today - February 18th, 2023 [February 18th, 2023]
- Psychedelic Drug Effects, Side Effects & Dangers - January 25th, 2023 [January 25th, 2023]
- Psychedelics Decriminalization Project In Berkeley, Cal Includes ... - January 6th, 2023 [January 6th, 2023]
- Ancient mummified child was drugged with psychedelics before ritual ... - December 14th, 2022 [December 14th, 2022]
- The therapeutic potential of psychedelics - Science - December 14th, 2022 [December 14th, 2022]
- Changing Lives with Psychedelics: How Connecticut researchers are using magic mushrooms to help people overcome depression, OCD - WTNH.com - November 19th, 2022 [November 19th, 2022]
- Penis Envy Mushroom | Legal Psychedelics | Magic Mushroom - November 7th, 2022 [November 7th, 2022]
- Psychedelics. Discussing natural and synthetic friends. Science, News ... - November 5th, 2022 [November 5th, 2022]
- The Harms of Psychedelics Need to Be Put Into Context - WIRED - November 5th, 2022 [November 5th, 2022]
- Packers' Aaron Rodgers says psychedelics led to his back-to-back MVP ... - October 28th, 2022 [October 28th, 2022]
- With Promise of Legalization, Psychedelic Companies Joust Over Future Profits - The New York Times - October 25th, 2022 [October 25th, 2022]
- How do psychedelics work? This brain region may explain their effects - PBS - October 21st, 2022 [October 21st, 2022]
- Why is the American right suddenly so interested in psychedelic drugs? - The Guardian - October 19th, 2022 [October 19th, 2022]
- Can Psychedelics Cure? Science Is on the Verge of Finding Out - Newsweek - October 19th, 2022 [October 19th, 2022]
- Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development - PsyPost - October 19th, 2022 [October 19th, 2022]
- This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More - Small Pharma - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Made the Mushrooms Magic: Psychedelic Study Explores the Odd Evolution of Mind-Altering Fungi - The Debrief - October 19th, 2022 [October 19th, 2022]
- Psychedelics And Wellness: The Healing Company Buys PepsiCo-Backed Superfoods Company - (HLCO) - Benzinga - October 19th, 2022 [October 19th, 2022]
- What's on the Colorado ballot? Housing, psychedelics, school meals, alcohol, taxes and more | FOX31 Denver - FOX 31 Denver - October 19th, 2022 [October 19th, 2022]
- DoseConnect to Sponsor the Tech Stage at Wonderland Miami by Microdose - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Is Going on With Bright Minds (DRUG) Stock Today? - InvestorPlace - October 19th, 2022 [October 19th, 2022]
- Psychedelics May Ease Fear of Death and Dying - October 17th, 2022 [October 17th, 2022]
- TDR's Top 5 Psychedelic Developments For The Week Of October 10 - The Dales Report - October 17th, 2022 [October 17th, 2022]
- DEA Wants To Boost Production Of Cannabis & Psychedelics For Research In 2023 - Benzinga - October 17th, 2022 [October 17th, 2022]
- Talk set to explore psychedelics and mental health - Reading Today - October 17th, 2022 [October 17th, 2022]
- Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- How does psilocybin rewire the brain? - Open Access Government - October 17th, 2022 [October 17th, 2022]
- HYTN Awarded Controlled Drugs and Substances Dealers License Allowing for Production and Sale of Psilocybin - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- The Healing Company acquires leading superfoods business, Your Super, and lands $150M credit facility to expand community of brands - Yahoo Finance - October 17th, 2022 [October 17th, 2022]